From the Independent Expert ...

Lots to read, but the import bit for me from the Independent Expert (page 30):

"117 Whilst it is not possible to reliably determine the value of either company, prima facie, in our opinion Mach7 shares are likely to have a substantially greater value than 3DM shares. This is primarily because Mach7’s software product has achieved revenues of US$5.7 million in 2015 and was recently named Medical Imaging Product Of The Year by Frost & Sullivan in October 2015. In contrast, 3DM has not yet achieved any material revenues, being at an earlier stage as regards product development.

118 Accordingly, in our opinion, the terms of the transaction favour 3DM shareholders, as 3DM shareholders appear to be contributing significantly less than 50% of the combined entity’s value but are retaining 51% ownership interest in the enlarged entity upon completion. 119 In our opinion the Proposal is therefore reasonable to 3DM shareholders."

Seems like a good proposition for 3DM shareholders IMO and a good time to buy before the exchange.